However, the GLP-1 agonist group exhibited an increased risk of hypercalcemia (2.3% vs. 1.1%, RR 2.02, 95% CI: 1.69–2.42, p < 0.001) and a slight elevation in neuropsychiatric symptoms, with depression/hallucination/confusion being more common in the treated group (13.5% vs. 11.4%, p < 0.001; RR 1.18, 95% CI: 1.11–1.25). This evidence concerns the gene GLP1R and depressive symptom measurement.